Healthcare
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer baseToronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio...
About this update from Tempramed Technologies Ltd.
Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer base Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the largest healthcare marketplaces in the United States. Highlights of the Partnership: McKesson Medical-Surgical is one of the largest and most established B2B healthcare distributors in North America, providing TempraMed with immediate access to a highly diversified and recurring customer base across non-acute care settings. This partnership marks a significant step in TempraMed's transition toward a more diversified revenue model, complementing its growing retail pharmacy footprint with scalable B2B distribution channels. The inclusion of TempraMed's full product portfolio across McKesson Medical-Surgical's sales and distribution network is expected to enhance product visibility, streamline procurement for healthcare providers, and accelerate adoption of the Company's proprietary thermal protection solutions across multiple care settings. Ron Nagar, CEO of TempraMed, commented: "Our relationship with McKesson Medical-Surgical represents an important step in advancing our North American commercial strategy. Through this distribution arrangement, TempraMed expects to improve access to its temperature management solutions across a broader range of non-acute care providers and healthcare channels. By making our full portfolio available through McKesson Medical-Surgical's distribution network, we aim to simplify product availability for healthcare professionals and patients managing temperature-sensitive medications. We believe this expanded reach will support broader market awareness and facilitate future commercial growth.
View stock analysis, news, and events for Tempramed Technologies Ltd.